← All trials

NCT04668157

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Feb 8, 2021
Primary completion
Jan 22, 2024
Completion date
Jan 22, 2024
First posted
Dec 16, 2020
Last posted
Dec 16, 2020
Enrollment
10
Arms / groups
1 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.